





Letters to the EditorTo the Editor:
In response to the article by Kelly et al., human Dendritic Cell
(DC) subset deﬁnition has become an area of interest due to the
varying functions of the subsets within blood [1].
In human blood, DC can be divided into plasmacytoid and
myeloid subtypes. Plasmacytoid DC are CD303+ and can be fur-
ther divided into CD2+ and CD2 [2]; myeloid DC are CD11c+
and can be further divided into CD1c+ and CD141+.
Blood CD141+ myeloid DC have gained particular attention
due to their homology to mouse CD103+ DC, which are capable
of cross-presentation and stimulation of CD8+ cytotoxic T cells
in viral and cancer immunotherapy. This subset is deﬁned by
its exclusive expression of a receptor involved in the recognition
of apoptotic cells known as C-type lectin 9A, or Clec9a [3].
In tissues, unlike human blood, CD141 expression is not exclu-
sive to CD141 DC [3] and tissue DC subsets cannot be deﬁned
solely by this marker, as CD141 is widely expressed both on mye-
loid and non-myeloid cells. Endothelial cells [4] and indeed the
major subsets of DC all express CD141 in the liver [5].
Clec9a in combination with high expression of CD141 has
been shown to more accurately deﬁne this tissue DC subset
which correlates to the CD141 subset seen in blood [5]. In the
liver, as can be seen from the ﬂow cytometry data presented by
Kelly et al., CD141 is expressed at high levels on CD1c+ DC and
CD14+ antigen presenting cells (APC) compared to blood.
The selection of cells using CD141 alone interferes with the
interpretation of the functional data presented by Kelly et al
The use of magnetic sorting in a heterogeneous sample of
CD141 cells will isolate a variety of CD141+ cells in the liver
including large numbers of pDC, CD1c+ DC and CD14+ DC
potentially confounding the results. The immunocytochemistry
photomicrograph presented in Fig. 2a demonstrates numerous
cells with varying degrees of CD141 expression. Only a propor-
tion of these cells are the true CD141hi DC, and as a result the
functional assays in the study must be interpreted with this is
mind. The subset of cells within this large CD141+ heteroge-
neous population responsible for a pro-inﬂammatory response
in the liver (as described in the paper) has not been accurately
deﬁned.
Perfusate is a partial representation of the cells found within
the liver; in particular it represents transient cells that ﬂux into
the systemic circulation. Although perfusate does contain a large
number of liver-derived DC, it does not include cells that are res-
ident within the liver and do not detach during pre-transplanta-
tion perfusion [6]. Analysis of the perfusate is potentially biased
towards certain populations of cells that are less adherent to tis-
sue. Perfusate is useful tissue for analysis, especially considering
the relative ease with which it can be acquired, but in order to
obtain a more thorough understanding of the entire population
of cells, it is necessary to analyse tissue-resident cells harvested
from whole liver tissue. A bias will be introduced by all methodsOpen access undeDendritic cell subset composition
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within the extravascular space and travel to draining lymph
nodes, it is likely that not all populations of DC have been
included in the study.
The paper by Kelly et al. is one of the ﬁrst representative
descriptions of DC from normal liver using multicolour ﬂow
cytometry. It provides some valuable insight and detail into the
subset composition of DC in human liver perfusates. The descrip-
tion of a CD141+ population of DC that co-expresses Clec9a is
consistent with the DC literature. Yet, isolating DC populations
on the basis of one marker alone, such as CD141, may give an
inaccurate representation of the functional aspects of the DC rep-
ertoire within the liver, and does not focus on the Clec9a popula-
tion of cells. In addition, analysing the cell populations within the
liver rather than from perfusate would be more informative than
the actual intrahepatic DC composition. Analysis of DC derived
from whole normal liver tissue using Fluorescence Assisted Cell
Sorting (FACS) as an adjunct to multicolour ﬂow cytometry, will
allow for more accurate isolation of subsets based on the expres-
sion of a combination multiple markers as his been shown in
other tissues [7]. In a complex tissue such as liver this level of
detail is required to accurately deﬁne a DC subset for investiga-
tion of changes in disease and identify future targets for thera-
peutic strategies.
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is more complex than it seems’’
To the Editor:
We read with interest the letter from Strauss and Bartlett regard-
ing our study of Dendritic Cells (DCs) in healthy human liver [1]
and would like to develop several of the points they raise. CD141
is a type 1 membrane receptor that binds thrombin and is nor-
mally expressed by endothelial cells [2]. Its role on the surface
of immune cells remains a puzzle and the functional relevance
of variable expression by subsets of DCs is not known. DCs
obtained from some organs, e.g., the skin, express CD141 on both
CD14 and CD14+ subsets of antigen presenting cells [3]. How-
ever, the majority of liver DCs expressing CD141 are CD11c+
and CD14 [1,3]. In addition, neither CD123+ plasmacytoid DCs
nor CD1c+ myeloid DC subsets appear to express high levels of
CD141 in the liver [1]. Extensive functional analyses of these sub-
sets are required before the puzzle can be solved, a particularly
challenging task given the small numbers of cells and difﬁculty
of getting healthy human tissue.
For functional characterisation of hepatic CD141+ DCs we
used a magnetic bead isolation method which was chosen in
order to maximize yield and limit activation or contamination
due to ﬂow sorting, as did Lauterbach et al., 2010 [4] for their
demonstration of IFN-k production from blood CD141+ DCs. To
increase purity, we ran our samples over two columns as per
manufacturer instructions, resulting in cell populations that were
highly enriched for CD141+ cells. (High CD141 expressing DCs are
clearly distinguishable from low CD141 expressors in the
immuno-ﬂuorescence image in Fig. 2A, which is of a mixed pop-
ulation of liver immune cells.)
Since we began this work, the CLEC9a marker was established
as a useful marker of DC subsets when used together with CD141
and we found that the CD141 high population of DCs in the liver
also co-expressed CLEC9a. Future work on this population of cells
would be best served by isolation of double positive
CD141+CLEC9a+ cells. Complete characterisation of the entire
antigen-presenting cell repertoire of the liver may well require
addition of even more immune cell markers.
Use of liver perfusate as a source of liver resident APCs cer-
tainly has its limitations. We may well be studying cell popula-
tions that have higher migratory properties than others. We
observe lower frequencies of iNKT cells in liver perfusate (unpub-
lished data) compared to what we [5] and others have found in
liver biopsies, suggesting that this particular population is less
migratory than conventional NK cells. However there is still no
ideal method for the study of minor cell subsets from healthy
human liver tissue. Too many markers are required to accurately
deﬁne DC subsets to use immunohistochemistry. Digestion of tis-
sue prior to ﬂow cytometry may also skew results, if, as previ-
ously demonstrated [6], certain epitopes are sensitive to
digestion enzymes. Also rare cell subsets may be lost in the mul-
tiple washing steps required in such methods. DCs are at too low
frequency to study in liver biopsies and they are unlikely to be
normal if obtained from tumour bearing liver tissue as signiﬁcant
differences in iNKT, and monocyte populations as well as cyto-
kine levels [7–9] have been found in liver tissue from patients
undergoing resection when compared with healthy liver. More-
over, it has recently been demonstrated that tumour microenvi-
ronment profoundly suppresses DC function [10]. Perhaps DC
subset distribution and function in healthy liver tissue may be
better explored using alternative methods in centres where ade-
quate tissue might be obtained, e.g., during resizing of liver for
paediatric transplantation.
It is clear that the CD141+ population of DCs is heterogeneous
as evidenced by differing expression of ILT3 and ILT4 [1]. The
presence of these subsets in both healthy and diseased livers
warrants further study. While some liver resident DCs may be
tolerogenic, our work clearly illustrates the ability of CD141+
DCs from healthy human liver to secrete inﬂammatory cytokines
and drive T cell responses. These proinﬂammatory liver resident
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